These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 12409716)

  • 1. Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial.
    Bullock MJ; Srigley JR; Klotz LH; Goldenberg SL
    Am J Surg Pathol; 2002 Nov; 26(11):1400-13. PubMed ID: 12409716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study.
    Montironi R; Diamanti L; Santinelli A; Galetti-Prayer T; Zattoni F; Selvaggi FP; Pagano F; Bono AV
    Pathol Res Pract; 1999; 195(4):201-8. PubMed ID: 10337657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
    Fair WR; Betancourt JE
    Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological changes of high-grade prostatic intraepithelial neoplasia and prostate cancer after monotherapy with bicalutamide 150 mg.
    Scattoni V; Montironi R; Mazzucchelli R; Freschi M; Nava L; Losa A; Terrone C; Scarpa RM; Montorsi F; Pappagallo G; Rigatti P
    BJU Int; 2006 Jul; 98(1):54-8. PubMed ID: 16831143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate.
    Iczkowski KA; Qiu J; Qian J; Somerville MC; Rittmaster RS; Andriole GL; Bostwick DG
    Urology; 2005 Jan; 65(1):76-82. PubMed ID: 15667867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of neoadjuvant treatment in clinically confined prostate cancer. Takeda NHT Italian Group.
    Prezioso D; Lotti T; Montironi R; Polito M
    Eur Urol; 1999; 35 Suppl 1():17-21; discussion 22. PubMed ID: 10081698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group.
    Klotz LH; Goldenberg SL; Jewett M; Barkin J; Chetner M; Fradet Y; Chin J; Laplante S
    Urology; 1999 Apr; 53(4):757-63. PubMed ID: 10197852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of the Gleason scoring system after neoadjuvant hormonal therapy.
    Bentley G; Dey J; Sakr WA; Wood DP; Pontes JE; Grignon DJ
    Mol Urol; 2000; 4(3):125-;discussion 131. PubMed ID: 11062366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-grade foamy gland prostatic adenocarcinoma on biopsy or transurethral resection: a morphologic study of 55 cases.
    Zhao J; Epstein JI
    Am J Surg Pathol; 2009 Apr; 33(4):583-90. PubMed ID: 19033862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up.
    Gleave ME; La Bianca SE; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
    Urology; 2000 Aug; 56(2):289-94. PubMed ID: 10925096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
    Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
    Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of pathological stage before neoadjuvant androgen withdrawal therapy and radical prostatectomy. The Canadian Urologic Oncology Group.
    Rabbani F; Goldenberg SL; Klotz LH
    J Urol; 1998 Mar; 159(3):925-8. PubMed ID: 9474184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
    Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
    J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Followup interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels.
    Lefkowitz GK; Taneja SS; Brown J; Melamed J; Lepor H
    J Urol; 2002 Oct; 168(4 Pt 1):1415-8. PubMed ID: 12352407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases.
    Tavora F; Epstein JI
    Am J Surg Pathol; 2008 Jul; 32(7):1060-7. PubMed ID: 18496142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial high-grade prostatic intraepithelial neoplasia with carcinoma on subsequent prostate needle biopsy: findings at radical prostatectomy.
    Al-Hussain TO; Epstein JI
    Am J Surg Pathol; 2011 Aug; 35(8):1165-7. PubMed ID: 21716083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No residual tumor in a radical prostatectomy specimen after neoadjuvant hormonal therapy for localized prostate cancer.
    Noguchi M; Noda S; Nakashima O; Kojiro M
    Oncol Rep; 2002; 9(5):1075-80. PubMed ID: 12168076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced annexin II protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer.
    Yee DS; Narula N; Ramzy I; Boker J; Ahlering TE; Skarecky DW; Ornstein DK
    Arch Pathol Lab Med; 2007 Jun; 131(6):902-8. PubMed ID: 17550317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues.
    Chang SS; Reuter VE; Heston WD; Hutchinson B; Grauer LS; Gaudin PB
    Cancer; 2000 Jan; 88(2):407-15. PubMed ID: 10640975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostatic adenocarcinoma with glomeruloid features.
    Pacelli A; Lopez-Beltran A; Egan AJ; Bostwick DG
    Hum Pathol; 1998 May; 29(5):543-6. PubMed ID: 9596281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.